The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Prescient Therapeutics (PTX) unveils its new cell therapy manufacturing enhancement technology, CellPryme-M
  • CellPryme-M is a platform technology that produces superior cells which are able to withstand cancer-killing activity for a longer duration than conventional CAR-T cells
  • The company will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter collaborations with external parties
  • In a show of confidence, Prescient says it will be its own first customer by using the therapy to enhance its internal programs
  • Shares in Prescient Therapeutics are down 9.09 per cent to $0.20 as of 12:30 pm AEST

Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.

CellPryme-M is a platform technology that produces superior cells during the cell manufacturing process. These cells are said to be less prone to exhaustion, which enables it to withstand cancer-killing activity for a longer period of time, and are capable of improved tumour trafficking and penetrance, compared to the current generation of CAR-T cells.

CellPrymeM CAR-T cells were also shown to perform better than conventional CAR-T cells in highly aggressive solid cancer models, and is now ready for use in clinical studies.

Prescient said it plans to use CellPryme-M to enhance the cells used in its breakthrough OmniCAR programs.

The clinical stage oncology company will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter collaborations with external parties.  

“CellPryme-M also opens up an entirely new business opportunity to license CellPryme-M to other cell therapy companies,” Prescient Managing Director and CEO Steven Yatomi-Clarke said.

“It requires minimal intervention into existing and emerging manufacturing process and therefore represents a relatively low implementation hurdle. This opens up real commercial opportunities for Prescient to incorporate CellPryme-M into third party manufacturing processes.”

“However, in a real show of confidence, Prescient will be it is own first customer by using it to enhance its internal OmniCAR programs, to combine next-gen CAR-T capabilities with superior cell phenotypes,” Steven Yatomi-Clarke said.

Shares in Prescient Therapeutics are down 9.09 per cent to $0.20 as of 12:30 pm AEST.

PTX by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…